New Indication Approval For Incyte “To Usher New Growth Avenue”
JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ:INCY) based on…
HC Wainwright Starts Coverage On This ‘Best-In-Class Agent For Inflammatory Disorders
HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class…
What’s Happening With Addex Therapeutics Shares Today
Addex Therapeutics Ltd (NASDAQ:ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share…
European Central Bank Raises Interest Rates After 11 Years, By More Than Expected
The European Central Bank (ECB) raised its benchmark deposit rate by 50 basis points to 0%, breaking its earlier guidance for…
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating…
Amazon Bets Almost $4B On Primary Health Care Provider To Deepen Its Presence In Healthcare
Amazon.com Inc (NASDAQ:AMZN) will acquire 1life Healthcare Inc (One Medical) (NASDAQ:ONEM) for $18 a share in an all-cash deal valuing the…
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
IQVIA’s Q2 Earnings Surpass Expectations; Forex Hits FY22 Top-Line Forecast
IQVIA Holdings Inc (NYSE:IQV) posted Q2 sales of $3.54 billion, up 3% Y/Y on a reported basis and 7.1% at…
Tabula Rasa Sees Better Than Expected Q2 Sales, Just As Investor Calls For Removal Of Top Executives
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) expects Q2 sales of $72 – $73 million, exceeding the prior guidance range of $66…
X4 Pharma To Stop Further Work On Oncology Programs, Looks For Partner(s)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) updated its strategic priorities that include streamlining resources to focus on advancing its lead candidate, mavorixafor, in…